REPORT

Longitudinal plasma p-tau217 is increased in early stages of Alzheimer’s disease

Niklas Mattsson-Carlgren,1,2,3 Shorena Janelidze,1 Sebastian Palmqvist,1,4 Nicholas Cullen,1,3 Anna L. Svenningsson,1,4 Olof Strandberg,1 David Mengel,5 Dominic M. Walsh,5 Erik Stomrud,1,4 Jeffrey L. Dage6 and Oskar Hansson1,4

See Teunissen et al. (doi:10.1093/brain/awaa329) for a scientific commentary on this article.

Plasma levels of tau phosphorylated at threonine-217 (p-tau217) is a candidate tool to monitor Alzheimer’s disease. We studied 150 cognitively unimpaired participants and 100 patients with mild cognitive impairment in the Swedish BioFINDER study. P-tau217 was measured repeatedly for up to 6 years (median three samples per person, median time from first to last sample, 4.3 years). Preclinical (amyloid-β-positive cognitively unimpaired, n = 62) and prodromal (amyloid-β-positive mild cognitive impairment, n = 49) Alzheimer’s disease had accelerated p-tau217 compared to amyloid-β-negative cognitively unimpaired (β = 0.56, P < 0.001, using linear mixed effects models) and amyloid-β-negative mild cognitive impairment patients (β = 0.67, P < 0.001), respectively. Mild cognitive impairment patients who later converted to Alzheimer’s disease dementia (n = 40) had accelerated p-tau217 compared to other mild cognitive impairment patients (β = 0.79, P < 0.001). P-tau217 did not change in amyloid-β-negative participants, or in patients with mild cognitive impairment who did not convert to Alzheimer’s disease dementia. For 80% power, 109 participants per arm were required to observe a slope reduction in amyloid-β-positive cognitively unimpaired (71 participants per arm in amyloid-β-positive mild cognitive impairment). Longitudinal increases in p-tau217 correlated with longitudinal worsening of cognition and brain atrophy. In summary, plasma p-tau217 increases during early Alzheimer’s disease and can be used to monitor disease progression.

1 Clinical Memory Research Unit, Faculty of Medicine, Lund University, Lund, Sweden
2 Department of Neurology, Skåne University Hospital, Lund University, Lund, Sweden
3 Wallenberg Center for Molecular Medicine, Lund University, Lund, Sweden
4 Memory Clinic, Skåne University Hospital, Malmö, Sweden
5 Laboratory for Neurodegenerative Research, Ann Romney Center for Neurologic Diseases, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA, USA
6 Eli Lilly and Company, Indianapolis, IN, USA

Correspondence to: Niklas Mattsson-Carlgren
Clinical Memory Research Unit, Memory Clinic, Skåne University Hospital, SE-20502
Malmö, Sweden
E-mail: niklas.mattsson@med.lu.se
Correspondence may also be addressed to: Oskar Hansson
E-mail: oskar.hansson@med.lu.se

Keywords: biomarker; plasma; p-tau; p-tau217; Alzheimer’s disease

Abbreviations: MCI = mild cognitive impairment; MMSE = Mini-Mental State Examination; mPACC = modified Preclinical Alzheimer’s Cognitive Composite; NfL = neurofilament light; p-tau = phosphorylated tau
Introduction

Minimally invasive blood-based biomarkers have the potential to improve clinical management of Alzheimer’s disease and design of clinical trials. Promising results have been reported for blood-based biomarkers for core features of Alzheimer’s disease, including amyloid-β peptides (Palmqvist et al., 2019b; Schindler et al., 2019), neurodegeneration biomarkers (including neurofilament light, NfL) (Mattsson et al., 2017, 2019), and phosphorylated tau (p-tau) (Mielke et al., 2018, Janelidze et al., 2020a; Thijssen et al., 2020). Plasma p-tau measures have been validated against CSF p-tau, and PET measurements of tau. Multiple tau phosphorylation epitopes exist, of which p-tau181 and p-tau217 have been studied as biomarkers (Barthélémy et al., 2020). In CSF, p-tau217 performs better than p-tau181, both for diagnosis of Alzheimer’s disease, and for correlations with tau PET (Janelidze et al., 2020b). We have recently found similar results for plasma p-tau217 when compared to p-tau181 (Palmqvist et al., 2020), but data are lacking on longitudinal plasma p-tau217, and its use for monitoring disease progression. We therefore measured plasma p-tau217 over time in cognitively unimpaired individuals, and in patients with mild cognitive impairment (MCI). We tested if p-tau217 increased over time at the preclinical (amyloid-β+ cognitively unimpaired) and prodromal stages (amyloid-β+ MCI) of Alzheimer’s disease, and if the trajectories differed between Alzheimer’s disease and other causes of cognitive impairment. For comparison, we included a non-specific marker of neurodegeneration (plasma NfL). We also tested if changes in p-tau217 correlated with changes in cognition or atrophy.

Materials and methods

Participants

Participants were recruited in the prospective Swedish BioFINDER study (www.biofinder.se), including cognitively unimpaired individuals (cognitively healthy controls or individuals with subjective cognitive decline, SCD), and patients with MCI. Details on recruitment, exclusion and inclusion criteria have been presented previously (Mattsson et al., 2016; Ossenkoppele et al., 2018). All subjects underwent lumbar puncture at baseline for CSF sampling. Plasma samples were taken at baseline and every second year for up to 6 years. Clinical assessments for determination of conversion to dementia were done annually (Table 1).

Fluid biomarkers

Plasma p-tau217 was measured using immunoassays at Lilly Research Laboratories (Palmqvist et al., 2019a). Plasma NfL was measured using the Quanterix NfL Advantage kit as described before (Mengel et al., 2020). A few outliers were removed for NfL (concentrations > mean + 3 standard deviations (SD)), n = 8 of 668 data-points. CSF amyloid-β42 and amyloid-β40 were measured using Meso Scale Discovery immunoassays (MSD). The CSF amyloid-β42/amyloid-β40 ratio (pathological if < 0.091) was used to determine amyloid-β-positivity (Janelidze et al., 2016).

Cognitive measures

We used the Mini-Mental State Examination (MMSE) (Folstein et al., 1975) and a cognitive composite (modified Preclinical Alzheimer’s Cognitive Composite, mPACC) (Donohue et al., 2014). The mPACC was calculated as the average of five z-scores, for tests of memory [the delayed recall test from the cognitive subscale from the Alzheimer’s Disease Assessment Scale (ADAS-cog), counted twice in order to preserve the weight on memory from the original PACC (Donohue et al., 2014)], verbal ability (animal fluency), executive function (Trail Making Test B) (Delis et al., 2001), and global cognition (MMSE). Animal fluency was included since category fluency tests may improve detection of early cognitive decline related to amyloid-β pathology (Papp et al., 2017). We restricted the cognitive test data to assessments done within 1 year of plasma sampling.

MRI measures

Anatomical T1-weighted imaging was performed on a 3 T magnetic resonance scanner (Siemens Tim Trio 3T) producing MP-RAGE images (repetition time = 1.950 ms, echo time = 3.4 ms, 1 mm isotropic voxels, 178 slices) used in the anatomical segmentation and cortical thickness calculations. These were performed using the Freesurfer image analysis pipeline v6.0 (http://surfer.nmr.mgh.harvard.edu/), where each time points’ scan was first processed separately. After brain extraction and intensity homogeneity correction, grey and white matter segmentation using intensity gradient and voxel connectivity, cortical modelling allowed parcellation of cerebral cortex into subunits of gyral and sulcal structure. Cortical thickness was measured as the distance from the grey–white matter boundary to corresponding pial surface. Reliable thickness and volume measures were then extracted by entering each subject’s processed scans at various time points into Freesurfer’s longitudinal stream (Reuter et al., 2012), creating an unbiased within-subject template over all time points, then used to improve robustness of several processing steps and increase reliability of final results. For the analyses in this paper, we used cortical thickness (adjusted for surface area) from a temporal meta-region of interest (consisting of bilateral entorhinal, fusiform, inferior temporal and middle temporal cortex) and hippocampal volume (averaged between the hemispheres). We restricted the MRI data to scans done within 1 year of plasma sampling.

Statistical analysis

First, we tested longitudinal p-tau217 changes in linear mixed effects (LME) models. We tested the interaction between time and amyloid-β status as a predictor in both cognitively unimpaired and MCI. We also tested the interaction between time and conversion to Alzheimer’s disease dementia as a predictor in MCI. Similar models were fitted for NfL. The LME models were adjusted for age and sex and included random intercepts and slopes. Risk for conversion to Alzheimer’s disease dementia was also tested in a Cox survival analysis. Second, a power

Longitudinal plasma p-tau217 in Alzheimer’s disease | 3235

BRAIN 2020: 143; 3234–3241
analysis (n = 500 bootstrap trials) was performed for p-tau217 in amyloid-β+ cognitively unimpaired and MCI groups, with trial duration assumed to be 48 months for cognitively unimpaired and 18 months for MCI, while follow-up was assumed to occur every 3 months. Third, associations were tested between longitudinal change in p-tau217 and longitudinal measures of cognition and brain structure, in LME models with the interaction between time and plasma p-tau217 slopes as the independent variable, adjusted for age, sex and (for cognitive measures) years of education or (for hippocampal volume) intracranial volume. Statistical analysis was done using R version 4.0.0. Significance was determined at P < 0.05 (two-tailed).

Data availability

Anonymized data will be shared by request from a qualified academic investigator for the sole purpose of replicating procedures and results presented in the article and as long as data transfer is in agreement with EU legislation on the general data protection regulation and decisions by the Ethical Review Board of Sweden and Region Skåne, which should be regulated in a material transfer agreement.

Results

Longitudinal plasma p-tau217 in different diagnostic groups

See Table 1 for demographics. During the clinical follow-up of all cases, 145 did not develop dementia, 48 developed Alzheimer’s disease dementia, and 36 developed other dementias (Table 1). Longitudinal p-tau217 data are shown in Fig. 1. In the cognitively unimpaired, p-tau217 had a trend towards higher levels in amyloid-β+ cognitively unimpaired compared to amyloid-β+ cognitively unimpaired at baseline [β = 0.50 (meaning 0.50 ng/l higher levels in amyloid-β+ cognitively unimpaired), P = 0.053], remained stable over time in amyloid-β+ cognitively unimpaired (β = 0.11, P = 0.30), and increased significantly over time in amyloid-β+ cognitively unimpaired compared to amyloid-β+ cognitively unimpaired (Fig. 1A) [time × amyloid-β-interaction: β = 0.56 (meaning an acceleration in amyloid-β+ of 0.56 ng/l per year, compared to the rate in amyloid-β+ cognitively unimpaired), P < 0.001; the increased rate corresponds to

Table 1  Demographics

|                      | Amyloid-β– CU | Amyloid-β+ CU | Amyloid-β– MCI | Amyloid-β+ MCI |
|----------------------|--------------|--------------|---------------|---------------|
| Clinical diagnosis   | n = 88       | n = 62       | n = 51        | n = 49        |
| Healthy controls     | 49/39/0      | 46/16/0      | 0/0/51        | 0/0/49        |
| SCD                  |              |              |               |               |
| Age, years           | 70.7 (4.9)   | 72.7 (5.2)   | 69.5 (5.8)    | 71.0 (5.2)    |
| M/F                  | 35/53        | 23/39        | 38/13         | 26/23         |
| Education, years     | 12.2 (3.0)   | 12.2 (3.7)   | 11.2 (3.4)    | 12.1 (3.5)    |
| APOE e4, +/-         | 67/21        | 26/36        | 38/13         | 11/38         |
| Baseline p-tau217, ng/l | 1.18 (1.64) | 1.71 (1.49) | 1.80 (1.74) | 4.56 (3.11) |
| Time from first to last p-tau217 sample, years | 5.2 (1.5) | 4.5 (1.2) | 2.7 (1.9) | 4.0 (2.0) |
| Number of plasma p-tau217 measures, 1/2/3/4 | 4/4/4/36 | 1/12/39/10 | 12/22/16/1 | 7/14/18/10 |
| Baseline NFL, ng/l   | 12.3 (5.0)   | 13.9 (5.8)   | 17.6 (8.5)    | 16.7 (7.1)    |
| Number of plasma NFL measures, 0/1/2/3/4 | 0/4/5/44/35 | 6/2/9/39/6 | 2/13/20/15/1 | 7/8/9/15/10 |
| MMSE at baseline, points | 29.1 (1.2) | 28.9 (1.1) | 27.5 (2.0) | 26.9 (1.7) |
| MMSE change/year, points | -0.05 (0.32) | -0.35 (0.65) | -1.00 (1.18) | -1.55 (1.12) |
| mPACC at baseline, points | 0.22 (0.63) | -0.17 (0.81) | -1.21 (0.71) | -1.51 (0.62) |
| mPACC change/year, points | -0.03 (0.13) | -0.13 (0.25) | -0.24 (0.29) | -0.34 (0.30) |
| Number of cognitive assessments, 0/1/2/3/4 | 1/4/32/22/57/1 | 0/1/13/32/23/1 | 2/12/16/12/8/1 | 0/7/11/19/8 |
| Time from first to last cognitive test, years | 5.2 (1.1) | 4.5 (1.0) | 3.5 (1.4) | 4.7 (1.3) |
| Conversion to dementia, none/non-AD dementia/AD dementia | 80/8/0 | 52/2/8 | 12/35/35 | 1/11/37 |
| Time-at-risk for dementia, years | 5.9 (1.4) | 5.1 (1.5) | 3.2 (1.8) | 3.0 (1.6) |
| Temporal cortical thickness at baseline, mm | 2.59 (0.16) | 2.52 (0.20) | 2.47 (0.22) | 2.45 (0.17) |
| Temporal cortical thickness change/year, points | -0.013 (0.015) | -0.028 (0.021) | -0.039 (0.042) | -0.065 (0.030) |
| Hippocampal volume at baseline, mm³ | 3363 (447) | 3250 (410) | 3297 (503) | 2899 (413) |
| Hippocampal volume change/year, points | -38 (28) | -57 (39) | -77 (58) | -94 (34) |
| Number of MRI scans, 0/1/2/3/4 | 10/2/15/36/25 | 6/2/12/34/8 | 15/5/17/12/2 | 8/4/9/19/9 |
| Time from first to last scan, years | 4.5 (1.6) | 4.2 (1.5) | 3.0 (1.8) | 3.9 (1.8) |

Continuous data are mean (SD). Time-at-risk for dementia was the overall clinical follow-up, or the time until a dementia diagnosis. The distribution of APOE e4 was balanced between males (53% APOE e4–, 47% APOE e4+) and females (60% APOE e4–, 40% APOE e4+, P = 0.33) (chi-square test). AD = Alzheimer’s disease; CU = cognitively unimpaired; SCD = subjective cognitive decline.

Amyloid-β– CU: six vascular dementia, one Parkinson’s disease dementia/Lewy body dementia, one frontotemporal lobe dementia; Amyloid-β+ CU: one Parkinson’s disease dementia/Lewy body dementia, one frontotemporal lobe dementia; Amyloid-β– MCI: 18 vascular dementia, 10 Parkinson’s disease dementia/Lewy body dementia, seven frontotemporal lobe dementia, one other dementia; Amyloid-β+ MCI: three vascular dementia, seven Parkinson’s disease dementia/Lewy body dementia, one frontotemporal lobe dementia.

*Data were missing on dementia conversion in one amyloid-β+ MCI patient.*
32.7% change per year from baseline in amyloid-β cognitively unimpaired.

In MCI, p-tau217 was significantly higher in amyloid-β+ MCI at baseline ($\beta = 2.65$, $P < 0.001$). Phosphorylated-tau217 levels remained stable over time in the amyloid-β–MCI group ($\beta = 0.12$, $P = 0.39$), whereas it increased in amyloid-β+ MCI (Fig. 1B) (time × amyloid-β–interaction: $\beta = 0.67$, $P = 0.00032$; the increased rate corresponds to 14.7% change per year from baseline in amyloid-β+ MCI).

P-tau217 was also higher at baseline in MCI patients who subsequently developed Alzheimer’s disease dementia (this included three amyloid-β– MCI patients, as the Alzheimer’s disease dementia diagnosis was blinded to biomarker results) compared to the remaining MCI group (including both stable MCI and MCI who converted to other dementias) ($\beta = 2.25$, $P < 0.001$). P-tau217 remained stable over time in MCI patients who did not develop Alzheimer’s disease dementia ($\beta = 0.053$, $P = 0.68$), but increased significantly over time in MCI to Alzheimer’s disease dementia converters (Fig. 1C) (time × conversion interaction: $\beta = 0.79$, $P < 0.0001$). These results for conversion to Alzheimer’s disease dementia were corroborated in a Cox survival analysis [hazard ratio (HR) = 1.25 (95% confidence interval, CI: 1.11–1.40), $P < 0.001$]. Similar results were obtained when stable MCI patients were excluded and the comparison was limited to MCI to Alzheimer’s disease dementia converters versus those with MCI who converted to other dementias (baseline difference: $\beta = 1.91$, $P = 0.002$; stable over time in non-Alzheimer’s disease MCI: $\beta = 0.020$, $P = 0.92$; acceleration in MCI to Alzheimer’s disease dementia converters; time × conversion interaction: $\beta = 0.82$, $P = 0.00054$).
Longitudinal plasma neurofilament light in different diagnostic groups

Results for plasma NfL are shown in the lower part of Fig. 1. Among the cognitively unimpaired (Fig. 1D), there was no effect of amyloid-β status at baseline NfL (P = 0.38). There was a slight increase over time in NfL in the cognitively unimpaired independent of amyloid-β status (main effect of time in amyloid-β cognitively unimpaired, β = 0.60, P < 0.001; no difference depending on amyloid-β status, P = 0.79). The findings were similar in MCI (Fig. 1E), with no effect of amyloid-β status at baseline (P = 0.57) and a slight increase over time (main effect of time in amyloid-β MCI, β = 1.47, P < 0.001; no difference depending on amyloid-β status, P = 0.45). MCI patients who did not convert to Alzheimer’s disease dementia had higher baseline plasma NfL compared with patients with MCI that converted to Alzheimer’s disease dementia (Fig. 1F, β = 4.62, P = 0.0095), but there was no difference over time depending on whether they converted to Alzheimer’s disease dementia or not (P = 0.78). The total number of observations available for plasma NfL was lower than for plasma p-tau217 (n = 660 versus n = 707). To ensure comparability between the NfL and p-tau217 results, we did a sensitivity analysis for p-tau217 restricted to samples where matching plasma NfL data were available. The results for p-tau217 were similar to the main analysis in this restricted set, both for amyloid-β cognitively unimpaired versus amyloid-β+ cognitively unimpaired (time × amyloid-β-interaction: β = 0.34, P < 0.001), amyloid-β+ MCI versus amyloid-β+ MCI (time × amyloid-β-interaction: β = 0.69, P < 0.001), and MCI to Alzheimer’s disease dementia converters versus the remaining MCI group (time × Alzheimer’s disease conversion interaction: β = 0.82, P < 0.001).

Power analyses to detect changes in plasma p-tau217

Power analyses showed that 109 participants per arm [interquartile range (IQR): 18, 282] would be required for 80% power to observe a reduction in slope for p-tau217 in amyloid-β+ cognitively unimpaired down to amyloid-β+ cognitively unimpaired levels, while 71 participants per arm (IQR: 53, 96) would be required for 80% power to see a reduction in slope in amyloid-β+ MCI down to amyloid-β+ MCI levels.

Longitudinal plasma p-tau217 and longitudinal cognition

We next tested associations between longitudinal plasma p-tau217 and longitudinal cognition (Fig. 2). Longitudinal increases in p-tau217 correlated with worsening cognition in both cognitively unimpaired and MCI, and also within the subgroups of amyloid-β+ participants. For each standard deviation higher slope of p-tau217, the decline in MMSE accelerated by β = −0.15 points (P < 0.001) in the overall cognitively unimpaired group (Fig. 2A), β = −0.13 points (P = 0.007) in the amyloid-β+ cognitively unimpaired group (Fig. 2B), β = −0.35 points (P < 0.001) in the overall MCI group (Fig. 2C), and β = −0.21 points (P = 0.004) per year in the amyloid-β+ MCI group (Fig. 2D). Corresponding accelerations in mPACC were β = −0.0048 points (P < 0.001) in the overall cognitively unimpaired group (Fig. 2E), β = −0.041 points (P = 0.0245) in the amyloid-β+ cognitively unimpaired group (Fig. 2F), β = −0.11 points (P < 0.001) in the overall MCI group (Fig. 2G), and β = −0.076 points (P = 0.0074) in the amyloid-β+ MCI group (Fig. 2H).

Longitudinal plasma p-tau217 and longitudinal atrophy

Finally, we tested associations between longitudinal plasma p-tau217 and longitudinal atrophy (Fig. 3). Longitudinally increased p-tau217 correlated with accelerated atrophy of temporal cortex and hippocampus in the amyloid-β+ cognitively unimpaired, amyloid-β+ cognitively unimpaired, and in the overall MCI group. For each standard deviation higher slope of p-tau217 the thinning of temporal cortex accelerated by β = −0.0057 mm (P < 0.001) per year in the overall cognitively unimpaired group (Fig. 3A), β = −0.0077 mm (P < 0.001) in the amyloid-β+ cognitively unimpaired group (Fig. 3B) and β = −0.0068 mm (P < 0.001) in the overall MCI group (Fig. 3C). The association in the amyloid-β+ MCI group was non-significant (Fig. 3D, β = −0.0031 mm, P = 0.16). Corresponding accelerations in atrophy of hippocampus were β = −7.56 mm³ (P < 0.001) per year in the overall cognitively unimpaired group (Fig. 3E), β = −11.8 mm³ (P < 0.001) in the amyloid-β+ cognitively unimpaired group (Fig. 3F), and β = −12.0 mm³ (P < 0.001) in the overall MCI group (Fig. 3G). The association in the amyloid-β+ MCI group was not statistically significant (Fig. 3H, β = −0.76 mm³, P = 0.72).

Discussion

Plasma p-tau217 increased over time in the preclinical (amyloid-β+ cognitively unimpaired) and early clinical stages (amyloid-β+ MCI and MCI to Alzheimer’s disease converters) of Alzheimer’s disease, but remained stable in the control groups, i.e. amyloid-β– cognitively unimpaired, amyloid-β– MCI, and MCI patients who did not convert to Alzheimer’s disease dementia. The changes were pronounced, giving high power to detect changes in a clinical trial scenario. Plasma NfL, a marker of neurodegeneration, did not show an Alzheimer’s disease-related increase over time in this cohort. The longitudinal changes in plasma p-tau217 correlated to longitudinal changes in cognition and brain atrophy. This was seen for both the overall cognitively unimpaired and MCI groups, as well as in the subgroups of participants with preclinical (for both cognitive and structural measures) and early clinical Alzheimer’s disease (for cognitive measures).
Taken together, our results demonstrate that plasma p-tau217 is a dynamic biomarker during early Alzheimer’s disease, which may be useful to monitor disease progression in clinical practice and in drug development, including to evaluate the effects of novel Alzheimer’s disease therapies. The clinically relevant longitudinal changes in plasma p-tau217, which correlate with both cognitive decline and (especially in the preclinical stage of the disease) increased brain atrophy, resemble previous reports of longitudinal changes of p-tau measures in CSF (Donohue et al., 2017; Falcon et al., 2018; Koychev et al., 2020). The fact that these clinically relevant tau-related changes can now be detected in plasma opens new venues of applied research. Already completed clinical trials (e.g. for promising anti-amyloid-β therapies) can be retrospectively tested for effects on plasma p-tau217. Banked longitudinal plasma samples in epidemiological studies can be analysed for p-tau217 to identify factors (e.g. demographic or genetic) that are associated with faster or slower development of tau pathology.

Note that since the individual subgroups were relatively small (e.g. n = 49 amyloid-β+ MCI), we may have been underpowered to detect significant correlations between changes in p-tau217 and some other measures (such as associations between changes in p-tau217 and changes in temporal cortex thickness in amyloid-β+ MCI, Fig. 3D).

To conclude, plasma p-tau217 levels accelerate over 6 years in preclinical and prodromal stages of Alzheimer’s disease. This can be used for minimally invasive, objective monitoring of disease progression in Alzheimer’s disease.

**Funding**

Work at the authors’ laboratory at Lund University was supported by the Swedish Research Council, the Wallenberg Center for Molecular Medicine, the Knut and Alice Wallenberg foundation, The Medical Faculty at Lund University, Region Skåne, the Marianne and Marcus Wallenberg foundation, the Strategic Research Area MultiPark (Multidisciplinary Research in Parkinson’s disease) at Lund University, the Swedish Alzheimer Foundation, the Swedish Brain Foundation, the Swedish Medical Association, the Konung Gustaf V:s och Drottning Victorias Frimurarestiftelse, the Bundy Academy, the Skåne...
University Hospital Foundation, and the Swedish federal government under the ALF agreement. D.M.W. is an Alzheimer’s Association Zenith Fellow. D.M. received support through a Research Fellowship from the German Research Foundation (DFG ME 4858/1-1).

Competing interests

O.H. has acquired research support (for the institution) from Roche, Pfizer, GE Healthcare, Biogen, Eli Lilly and AVID Radiopharmaceuticals. In the past 2 years, he has received consultancy/speaker fees (paid to the institution) from Biogen and Roche. J.L.D. is an employee of Eli Lilly and Company. D.M.W. is an employee of Biogen. All other authors report no competing interests.

References

Barthélémy NR, Li Y, Joseph-Mathurin N, Gordon BA, Hassenstab J, Benzinger TLS, et al. A soluble phosphorylated tau signature links tau, amyloid and the evolution of stages of dominantly inherited Alzheimer’s disease. Nat Med 2020; 26: 398–407.

Donohue MC, Sperling RA, Petersen R, Sun C-K, Weiner MW, Aisen PS. Association between elevated brain amyloid and subsequent cognitive decline among cognitively normal persons. Jama 2017; 317: 2305–16.

Donohue MC, Sperling RA, Salmon DP, Rentz DM, Raman R, Thomas RG, et al. The preclinical Alzheimer cognitive composite: measuring amyloid-related decline. JAMA Neurol 2014; 71: 961–70.

Falcon C, Tucholka A, Monté-Rubio GC, Cacciaglia R, Operto G, Rami L, et al. Longitudinal structural cerebral changes related to core CSF biomarkers in preclinical Alzheimer’s disease: a study of two independent datasets. Neuroimage Clin 2018; 19: 190–201.

Folstein MF, Folstein SE, McHugh PR. ‘Mini-mental state’. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975; 12: 189–98.

Janelidze S, Mattsson N, Palmqvist S, Smith R, Beach TG, Serrano GE, et al. Plasma P-tau181 in Alzheimer’s disease: relationship to other biomarkers, differential diagnosis, neuropathology and longitudinal progression to Alzheimer’s dementia. Nat Med 2020a; 26: 379–86.

Janelidze S, Stomrud E, Smith R, Palmqvist S, Mattsson N, Airey DC, et al. Cerebrospinal fluid p-tau217 performs better than p-tau181 as
a biomarker of Alzheimer’s disease. Nature Communications 2020b; 11: 1683.
Janelidze S, Zetterberg H, Mattsson N, Palmqvist S, Vanderstichele H, Lindberg O, et al. CSF Aβ42/Aβ40 and Aβ42/Aβ38 ratios: better diagnostic markers of Alzheimer disease. Ann Clin Transl Neurol 2016; 3: 154–65.
Koychev I, Vaci N, Bilgel M, An Y, Muniz GT, Wong DF, et al. Prediction of rapid amyloid and phosphotylated-Tau accumulation in cognitively healthy individuals. Alzheimer’s Dement Amst Neth 2020; 12: e12019.
Mattsson N, Andreasson U, Zetterberg H, Blennow K. Alzheimer’s disease neuroimaging initiative. Association of plasma neurofilament light with neurodegeneration in patients with Alzheimer disease. JAMA Neurol 2017; 74: 557–66.
Mattsson N, Cullen NC, Andreasson U, Zetterberg H, Blennow K. Association between longitudinal plasma neurofilament light and neurodegeneration in patients with Alzheimer disease. JAMA Neurol 2019; 76: 791–9.
Mengel D, Liu W, Glynn RJ, Selkoe DJ, Strydom A, Lai F, et al. Dynamics of plasma biomarkers in Down syndrome: the relative levels of Aβ42 decrease with age, whereas NT1 tau and NfL increase. Alzheimer’s Res Ther 2020; 12: 27.
Mielke MM, Hagen CE, Xu J, Chai X, Vemuri P, Lowe VJ, et al. Plasma phospho-tau217 increases with Alzheimer’s disease clinical severity and is associated with tau- and amyloid positron emission tomography. Alzheimers Dement J Alzheimers Assoc 2018; 14: 989–97.
Ossenkoppele R, Rabinovici GD, Smith R, Cho H, Scholl M, Strandberg O, et al. Discriminative Accuracy of [18F]flortaucipir Positron Emission Tomography for Alzheimer disease vs other neurodegenerative disorders. JAMA Neurolology 2018; 75: 1151–62.
Palmqvist S, Insel PS, Stomrud E, Janelidze S, Zetterberg H, Brix B, et al. Cerebrospinal fluid and plasma biomarker trajectories with increasing amyloid deposition in Alzheimer’s disease. JAMA Neurology 2019b; 76: 1060–69.
Palmqvist S, Janelidze S, Quiroz YT, Zetterberg H, Lopera F, Stomrud E, et al. Discriminative accuracy of plasma Phospho-tau217 for Alzheimer disease vs other neurodegenerative disorders. JAMA 2020; e2012134. doi: 10.1001/jama.2020.12134. Online ahead of print.
Palmqvist S, Janelidze S, Stomrud E, Zetterberg H, Carl J, Zink K, et al. Performance of fully automated plasma assays as screening tests for Alzheimer disease-related β-amyloid status. JAMA Neurol 2019b.
Papp KV, Rentz DM, Orlovsy I, Sperling RA, Mormino EC. Optimizing the preclinical Alzheimer’s cognitive composite with semantic processing: the PACC5. Alzheimers Dement Transl Res Clin Interv 2017; 3: 668–77.
Reuter M, Schmansky NJ, Rosas HD, Fischl B. Within-subject template estimation for unbiased longitudinal image analysis. Neuroimage 2012; 61: 1402–18.
Schindler SE, Bollinger JG Ovod V, Mawuenyega KG, Li Y, Gordon BA, et al. High-precision plasma β-amyloid 42/40 predicts current and future brain amyloidosis. Neurology 2019; 17: e1647–59.
Thijssen EH, La Joie R, Wolf A, Strom A, Wang P, Iaccarino L, et al. Diagnostic value of plasma phosphorylated tau181 in Alzheimer’s disease and frontotemporal lobar degeneration. Nat Med 2020; 26: 387–97.